A month has gone by since the last earnings report for Sage Therapeutics, Inc. (SAGE). Shares have lost about 11.1% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Sage Therapeutics (NASDAQ:SAGE) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Sage ...

The market expects Sage Therapeutics, Inc. (SAGE) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago.

In the last three months, 4 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise ...

BofA withdrew its rating on SAGE in January after the depression drug developer said that Biogen (NASDAQ:BIIB) agreed to buy ...

SAGE THERAPEUTICS ($SAGE) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$1.01 per share, beating estimates of -$1.04 by ...

$50,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and awareness of mental health ...

In this article, we are going to take a look at where Sage Therapeutics, Inc. (NASDAQ:SAGE) stands against the other ...

The latest price target for Sage Therapeutics (NASDAQ:SAGE) was reported by Needham on April 30, 2025. The analyst firm set a price target for $0.00 expecting SAGE to fall to within 12 months (a ...

Sage Therapeutics (NASDAQ:SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, noting that the impact of Biogen’s ...